Xbrane is a leading Swedish biosimilar which has an EU approval for launch of Ximluci, a Lucentis Biosimilar.

The product lunch is scheduled for 1Q2023.

Expect material re-rating as the sales come in. 3-4x times return candidate over 2 years horizon.

https://fitinvestmentideas.com/2022/11/28/xbrane-our-top-trade-idea-for-2023-24/